Press Release
BOSTON, July 27, 2026 (GLOBE NEWSWIRE) — Rose Hill Life Sciences (“Rose Hill” or “the Company”), a clinical-stage biotechnology company advancing psychedelic therapeutics for neurological and psychiatric conditions, announced the appointment of Jama Pitman as Chief Executive Officer. Pitman, who joined Rose Hill in May 2025 as Strategic Advisor, has been central to shaping the Company’s clinical development strategy, regulatory roadmap and commercialization planning. In her new role, she will lead Rose Hill’s organization as it advances its growing portfolio of clinical programs investigating psilocybin-based therapeutics across neurological and psychiatric conditions.
Pitman brings more than 25 years of global biopharmaceutical experience to the role, having guided companies through complex regulatory pathways, FDA approvals, IPO readiness and strategic transactions spanning oncology, rare diseases, and antiviral therapeutics. She previously served as Senior Vice President and Chief Development Officer at Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech to a global, multi-product company that was acquired for $2.4 billion. She is also the founder of JP BioPharma Consulting, where she has advised biotech and pharmaceutical companies on accelerating drug development and achieving corporate growth goals.
“Rose Hill is at a genuinely consequential moment in its evolution,” said Jama Pitman, CEO of Rose Hill Life Sciences. “With active clinical programs underway and a growing body of scientific evidence supporting psilocybin’s potential in areas of significant unmet need, the Company is positioned to make a meaningful contribution to the future of neurological and psychiatric medicine. I look forward to leading the team as we execute on our clinical, regulatory, and commercial strategy with rigor and discipline.”
Rose Hill is currently advancing the following programs investigating the therapeutic potential of psilocybin:
